Attorney General William H Sorrell has announced that Vermont will receive approximately $60,000 as part of a $72.5 million settlement with Novartis Pharmaceuticals Corporation and Novartis Vaccines & Diagnostics, Inc that involved 49 states, the District of Columbia and the federal government. The agreement with Novartis resolves allegations that the company promoted the use of tobramycin, a cystic fibrosis drug which is marketed under the trade name TOBI®, for uses not approved by the Food & Drug Administration. The off- label marketing included promoting the drug for diseases other than cystic fibrosis and for use in cystic fibrosis patients under the age of six. As a result of this settlement, Novartis will pay damages equal to double the amount that Vermont and other states expended for prescriptions written as a result of the company’s off- label promotion.
Source: VTAG. 5.6.2010
Vermont gets $60,000 in settlement against Novartis over cystic fibrosis drug
Submitted by tim
on